[go: up one dir, main page]

DE602004017201D1 - Nachweis einer histonmodifikation in zellfreien nukleosomen - Google Patents

Nachweis einer histonmodifikation in zellfreien nukleosomen

Info

Publication number
DE602004017201D1
DE602004017201D1 DE602004017201T DE602004017201T DE602004017201D1 DE 602004017201 D1 DE602004017201 D1 DE 602004017201D1 DE 602004017201 T DE602004017201 T DE 602004017201T DE 602004017201 T DE602004017201 T DE 602004017201T DE 602004017201 D1 DE602004017201 D1 DE 602004017201D1
Authority
DE
Germany
Prior art keywords
cell
free nucleosomes
evidence
nucleosomes
histone modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017201T
Other languages
English (en)
Inventor
Lindsay Jane Bawden
Elizabeth Ann Bone
Alan Hastings Drummond
Lindsey Ann Needham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Publication of DE602004017201D1 publication Critical patent/DE602004017201D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875Nucleoproteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
  • Geophysics And Detection Of Objects (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE602004017201T 2003-08-18 2004-08-18 Nachweis einer histonmodifikation in zellfreien nukleosomen Expired - Lifetime DE602004017201D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0319376.0A GB0319376D0 (en) 2003-08-18 2003-08-18 Histone modification detection
PCT/GB2004/003564 WO2005019826A1 (en) 2003-08-18 2004-08-18 Detection of histone modification in cell-free nucleosomes

Publications (1)

Publication Number Publication Date
DE602004017201D1 true DE602004017201D1 (de) 2008-11-27

Family

ID=28052702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017201T Expired - Lifetime DE602004017201D1 (de) 2003-08-18 2004-08-18 Nachweis einer histonmodifikation in zellfreien nukleosomen

Country Status (9)

Country Link
US (3) US9128086B2 (de)
EP (1) EP1668368B1 (de)
AT (1) ATE411525T1 (de)
DE (1) DE602004017201D1 (de)
DK (1) DK1668368T3 (de)
ES (1) ES2315697T3 (de)
GB (1) GB0319376D0 (de)
SI (1) SI1668368T1 (de)
WO (1) WO2005019826A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
CA2607327A1 (en) * 2005-04-29 2006-11-09 The Regents Of The University Of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
US8119572B2 (en) 2005-10-24 2012-02-21 Wisconsin Alumni Research Foundation Methods for determining protein binding specificity using peptide libraries
WO2012040523A2 (en) 2010-09-24 2012-03-29 The Rockefeller University Phosphohistidine analogs
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115099D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
EP3264090B1 (de) 2011-12-07 2022-05-18 Belgian Volition Srl Verfahren zur erkennung von nukleosomaddukten
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers
GB201303575D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes
EP2775304A1 (de) * 2013-03-07 2014-09-10 Universitätsspital Basel Verfahren zum Nachweis einer entzündlichen Störung
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP3213084B2 (de) 2014-10-29 2023-12-13 Belgian Volition SPRL Verfahren zur anreicherung von zirkulierendem tumor-dna
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
CN109415431A (zh) 2016-04-20 2019-03-01 爱兰细胞技术公司 与k180二甲基化h1.0蛋白相关的组合物和方法
TWI726009B (zh) * 2016-11-28 2021-05-01 比利時商比利時意志有限公司 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途
EP4011413A1 (de) 2017-09-18 2022-06-15 Santersus AG Verfahren und vorrichtung zur reinigung von blut aus zirkulierender zellfreier dna
CN111770761B (zh) 2017-10-25 2024-07-09 爱兰细胞技术公司 H1.0k180me2抗体、其制造方法和用途
GB201721569D0 (en) 2017-12-21 2018-02-07 Belgian Volition Sprl Method for the detection and treatment of colorectal adenomas
CA3088077A1 (en) * 2018-01-10 2019-07-18 Epicypher, Inc. Methods for quantification of nucleosome modifications and mutations at genomic loci and clinical applications thereof
CA3091807A1 (en) * 2018-03-01 2019-09-06 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes
CN112119166B (zh) * 2018-03-13 2025-08-22 耶路撒冷希伯来大学伊萨姆研发有限公司 无细胞dna染色质免疫沉淀的诊断应用
GB2587939B (en) 2018-04-02 2023-06-14 Grail Llc Methylation markers and targeted methylation probe panels
CN113286881A (zh) 2018-09-27 2021-08-20 格里尔公司 甲基化标记和标靶甲基化探针板
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
CN114901832A (zh) 2019-08-27 2022-08-12 比利时意志有限责任公司 分离循环核小体的方法
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
EP4435431A3 (de) 2019-12-02 2024-10-16 Belgian Volition SRL Verwendung von zellfreien nukleosomen als biomarker
MX2022011614A (es) 2020-03-20 2022-10-13 Belgian Volition Srl Metodo de triaje utilizando niveles de nucleosomas libres de celulas.
WO2022058604A1 (en) 2020-09-21 2022-03-24 Belgian Volition Srl Device for inline monitoring of free nucleosomes in blood
EP4237850A4 (de) * 2020-11-02 2024-09-18 Epicypher, Inc. Verbesserte assays zur quantifizierung von chromatinzielen mittels antikörpergerichtetem enzymabbau
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202238132A (zh) 2020-12-08 2022-10-01 比利時商比利時意志有限公司 多發性硬化症之診斷方法
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
JP2024542996A (ja) 2021-10-29 2024-11-19 ベルジアン ボリション エスアールエル 均一系免疫アッセイ法
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
US12053567B2 (en) 2021-12-27 2024-08-06 Santersus Ag Method and device for removal of circulating cell free DNA
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
EP4577835A1 (de) 2022-08-25 2025-07-02 Belgian Volition SRL Verfahren zum nachweis von demenz
EP4639165A1 (de) 2022-12-19 2025-10-29 Belgian Volition SRL Beurteilung biologischer proben zur nukleinsäureanalyse
WO2024133225A1 (en) 2022-12-19 2024-06-27 Belgian Volition Srl Calibration
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy
WO2024213795A1 (en) 2023-04-14 2024-10-17 Belgian Volition Srl Diagnosis method using cell free nucleosome levels
WO2024223947A1 (en) 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
GB202307768D0 (en) 2023-05-24 2023-07-05 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
GB202310137D0 (en) 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
WO2025012440A1 (en) 2023-07-13 2025-01-16 Belgian Volition Srl Method for detection of the potential of a body fluid sample to produce extracellular traps
WO2025061853A1 (en) 2023-09-19 2025-03-27 Belgian Volition Srl Lateral flow test device
WO2025093747A1 (en) 2023-11-02 2025-05-08 Belgian Volition Srl Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules
WO2025181348A1 (en) 2024-03-01 2025-09-04 Belgian Volition Srl Method for determining the origin of circulating dna
WO2025253002A1 (en) 2024-06-07 2025-12-11 Belgian Volition Srl Sample collection for liquid biopsy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2934299A (en) * 1998-03-18 1999-10-11 Roche Diagnostics Gmbh Detection of apoptotic products
WO2003014142A2 (en) 2001-08-03 2003-02-20 University Of Virginia Patent Foundation Phosphorylated histone h2b as an apoptosis marker
CN1606628A (zh) 2001-11-30 2005-04-13 辉瑞产品公司 检测染色体数量异常细胞的方法
AU2003216291A1 (en) * 2002-02-20 2003-09-09 Chroma Therapeutics Ltd. A non-invasive diagnostic test utilizing histone modification markers
WO2004080288A2 (en) * 2003-03-10 2004-09-23 University Of Virginia Patent Foundation Post-translational modifications of proteins as regulatory switches
GB0319376D0 (en) 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
CA2607327A1 (en) * 2005-04-29 2006-11-09 The Regents Of The University Of California Antibodies against histone modifications for clinical diagnosis and prognosis of cancer

Also Published As

Publication number Publication date
ES2315697T3 (es) 2009-04-01
GB0319376D0 (en) 2003-09-17
US10408831B2 (en) 2019-09-10
US20150330996A1 (en) 2015-11-19
US9128086B2 (en) 2015-09-08
EP1668368B1 (de) 2008-10-15
EP1668368A1 (de) 2006-06-14
ATE411525T1 (de) 2008-10-15
WO2005019826A1 (en) 2005-03-03
US20190353653A1 (en) 2019-11-21
US20070160989A1 (en) 2007-07-12
SI1668368T1 (sl) 2009-04-30
DK1668368T3 (da) 2009-02-23

Similar Documents

Publication Publication Date Title
DE602004017201D1 (de) Nachweis einer histonmodifikation in zellfreien nukleosomen
EP2275815A3 (de) Verbesserte Immunoassayverfahren
DE60228557D1 (de) Candida-nachweis
BRPI0618713B8 (pt) cardiolipina modificada e seus usos
WO2003070894A3 (en) A non-invasive diagnostic test utilizing histone modification markers
ATE474228T1 (de) Reagenz für hämoglobinabbau
EP2194380A3 (de) Nachweis eines Zielantigens ungeachtet der An- oder Abwesenheit eines entsprechenden therapeutischen Antikörpers
BRPI0610092B8 (pt) métodos para a detecção de um analito e de um ácido nucleico em uma amostra, e de sintetização de uma molécula de ácido nucleico ou de análogo de ácido nucleico, kit reagente, uso do mesmo, molécula de ácido nucleico ou de análogo de ácido nucleico e produto associado
GB2404022B (en) Competitive assays for the detection of methamphetamine group drugs
DE502005009914D1 (de) Bestimmung von felinem und caninem probnp
WO2008060376A3 (en) Algorithims for multivariant models to combine a panel of biomarkers for assessing the risk of developing ovarian cancer
EP1560025A3 (de) Marker spezifisch für Diabetes
EP2323059A3 (de) Systeme und Verfahren zur Vorhersage des Risikos einer rheumatoiden Arthritis
WO2005044989A3 (en) Polynucleotides and polypeptides of anaplasma phagocytophilum and methods of using the same
WO2008017363A3 (en) Improved immunoassay involving mutant antigens to reduce unspecific binding
ATE503187T1 (de) Nachweis eines therapeutischen antikörpers in einem versuchstier
WO2005102938A3 (en) Antibodies specific for bcr-abl fusion protein and uses thereof
ATE447711T1 (de) System zur internen, qualitativen und quantitativen überprüfung von zellmarker-indices
DE602004001994D1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
DE502006004301D1 (de) Diagnose von allergischen erkrankungen, atopischen erkrankungen und/oder autoimmunerkrankungen durch nachweis von autoantikörpern gegen cd28 in humanem serum
ATE440968T1 (de) Verfahren zur diagnostizierung von aspirinunverträglichkeit
WO2006124888A3 (en) Detection of antigen specific immunocomplexes
EP2407787A3 (de) Verfahren für den Nachweis von L523S-Expression in biologischen Proben
WO2005037056A3 (en) Method for the detection of a biomolecule in a test sample
Osbak Contemporary syphilis epidemics: efforts to improve syphilis diagnostics

Legal Events

Date Code Title Description
8364 No opposition during term of opposition